1, inert lymphoma Follicular lymphoma: with markers of all B; CD5-, CD10+, BCL-2+. 90% of patients have t(14;18)(q32;q21). (Note that normal lymphoid follicles are negative for BCL-2 when there is reactive hyperplasia). Small cell lymphoma: with full B markers, CD20+, CD79a+;CD5+, weak SmIg, CD23+, and cyclin D1 negative (note the comparison with MCL) . Marginal zone lymphoma: with markers of all B; CD5-, CD10-, BCL-2-. 50% of patients have t(11;19)(q21;q21), t(1;14)(q22;q32) is relatively rare, often with BCL-10 overexpression, and responds poorly to treatment for H. pylori clearance. 2, aggressive lymphoma Diffuse large cell lymphoma (DLBCL): has markers of all-B, CD20+, CD79a+; usually Ig+, Ki67 less than 90% of DLBCL patients have a better prognosis (note Burkitt’s lymphoma >99%); multiple unrecognized subtypes may exist; current application of DNA microarray The gene expression detected can be divided into two subgroups: germinal center origin (better prognosis) and activated B-cell origin (worse prognosis). 35% of patients have Der(3)(q27), which produces a Bcl-6 mutation; 25% have t(14;18); 15% have t(8;14). Mature (or peripheral) T-cell NHL: has markers for all-T cells, CD3+, CD2+; TdT negative (note positive TdT in pre-T lymphoblasts). Set-cell lymphoma: has markers for whole B cells, CD5+, patients have strong SIg expression, CD23-, cyclinD1+; 70% of patients have t(1;14)(q13;q32) translocations. Mesenchymal large-cell NHL: with markers of whole T cells, TdT -, CD30+, ALK+; 60% of patients have t(2;5)(q13;q32) translocations. 3. Highly aggressive lymphoma Burkitt’s lymphoma: has all-B markers, CD20+, CD79a+; usually Ig+, Ki67 >99% (note DLBCL lymphoma <90%). 80% of patients have t(8;14)(q24;q32) translocation; 15% of patients have t(2;8) (q11;q24); 5% of patients have t (8;22) (q24;q11) translocations, resulting in juxtaposition of the c-MYC gene with the Ig gene, causing overexpression of the MYC gene, but this is not helpful for diagnosis, as it is also expressed in normal cells or other types of lymphoma. The level of antibodies against EBV antigen titers is increased in endemic lymphoma cases and multiple copies of EBV DNA can be found in the tumor. Similar manifestations are seen in disseminated cases. Pro-B lymphoblastic leukemia/lymphoma: There are markers of all-B, Ig-, CD10+, TdT+. Pro-T lymphoblastoid leukemia/lymphoma: all-T marker, TdT+.